Contract notice
Section I: Contracting
authority
I.1) Name and addresses
Genomics England Ltd
Dawson Hall, Charterhouse Square
London
EC1M 6BQ
UK
Contact person: Paul Nicholson, Procurement Lead
Telephone: +44 2078825030
E-mail: paul.nicholson@genomicsengland.co.uk
NUTS: UKI
Internet address(es)
Main address: https://www.genomicsengland.co.uk
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://genomicsengland.bravosolution.co.uk/genomicsengland/web/login.html
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://genomicsengland.bravosolution.co.uk/genomicsengland/web/login.html
Tenders or requests to participate must be sent to the abovementioned address
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Other: Genomics
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Research Environment Clinical Data Platform
Reference number: GeL-RE-004-18
II.1.2) Main CPV code
72222300
II.1.3) Type of contract
Services
II.1.4) Short description
As part of 100 000 Genome Project, Genomics England established a secure Research Environment (RE) to contribute to the realisation of Genomics England’s target benefits which are:
— patient benefit,
— new scientific insights and discovery,
— accelerating the uptake of genomic medicine in the NHS,
— stimulating and enhancing UK industry and investment, and
— increasing public knowledge and support for genomic medicine.
Design, development and operation of the RE are driven by its objective to “provide a secure and collaborative workspace that enables researchers and industry to perform genomic data analysis to accelerate scientific discovery.”
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.2) Additional CPV code(s)
48000000
48100000
71600000
71621000
72000000
72212100
72262000
II.2.3) Place of performance
NUTS code:
UKI
Main site or place of performance:
London
II.2.4) Description of the procurement
As part of 100 000 Genome Project, Genomics England established a secure Research Environment (RE) to contribute to the realisation of Genomics England’s target benefits which are:
— patient benefit,
— new scientific insights and discovery,
— accelerating the uptake of genomic medicine in the NHS,
— stimulating and enhancing UK industry and investment, and
— increasing public knowledge and support for genomic medicine.
Design, development and operation of the RE are driven by its objective to “provide a secure and collaborative workspace that enables researchers and industry to perform genomic data analysis to accelerate scientific discovery.”
Below outlines the scope of the RE and the target capabilities that are being delivered as part of a programme of work. A brief description of the capabilities that are to be delivered are provided below.
People
— staff appropriately skilled to implement, maintain and support the required data platforms,
— recruitment and staff development that maintains the required skills within Genomics England,
— organisational structures and resources required to support the effective operation and improvement of the data platforms.
Policy and Process
— solutions that drive a standardised approach to data governance, consent practises, data release and other relevant policies and processes,
— solutions that enable effective management of data quality,
— policies and processes that enable users to work securely, efficiently and effectively in the Research Environment.
Technology
— software and infrastructure that meet functional, security, governance, capacity and performance requirements of the research environment,
— technology providing the usability, availability, accessibility, flexibility, interoperability and scalability required by both academic and commercial users.
A key component of the RE is a clinical data platform. The platform will accommodate unstructured, semi-structured and structured data.
Over and above the platform, there is a requirement for support services.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 60
This contract is subject to renewal: Yes
Description of renewals:
Initial contract length of 36 months with 2 options to renew for 12 month periods making the total possible contract length 60 months.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section III: Legal, economic, financial and technical information
III.1) Conditions for participation
III.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
III.1.3) Technical and professional ability
Selection criteria as stated in the procurement documents
III.2) Conditions related to the contract
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Restricted procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
No
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2018/S 207-472572
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
24/05/2019
Local time: 12:00
IV.2.3) Estimated date of dispatch of invitations to tender or to participate to selected candidates
Date:
07/06/2019
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
IV.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 3 (from the date stated for receipt of tender)
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
No
VI.2) Information about electronic workflows
Electronic invoicing will be accepted
Electronic payment will be used
VI.3) Additional information
The Contracting Authority expressly reserves the right
(i) not to award any contract as a result of the procurement process commenced by publication of this notice; and
(ii) to make whatever changes it may see fit to the content and structure of the tendering competition; and in no circumstances will the Contracting Authority be liable for any costs incurred by the candidates. Any expenditure, work or effort undertaken prior to contract award is accordingly a matter solely for the commercial judgement of potential suppliers.
(a) Genomics England reserves the right at any stage to reject or disqualify or revise the pre-qualified status of any tenderer who:
1) Provides information or confirmations which later prove to be untrue or incorrect; and/or
2) Does not submit a tender in accordance with the requirements of the tender document or as otherwise directed by Genomics England during the procurement process; and/or
3) Fulfils any one or more of the criteria detailed in the Public Contracts Regulations 2016 pertaining to Mandatory Exclusions.
(b) further information on Genomics England may be found at https://www.genomicsengland.co.uk/
(c) all discussions and meetings will be conducted in English;
(d) tenders and supporting documents must be priced in GBP and all payments under the contract will be made in sterling;
(e) Genomics England may interview any or all economic operators who express an interest in tendering for this work.
VI.4) Procedures for review
VI.5) Date of dispatch of this notice
17/04/2019